Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.31 |
| ▸ | REN | P00797 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL626315 | 1.00 | AAK1 (0.39) | AAK1MMP13MEN1GAAKMT2A | |
| SCHEMBL16972355 | 1.00 | AAK1 (0.39) | AAK1MMP13MEN1GAAKMT2A | |
| SCHEMBL9447853 | 0.86 | MMP13 (0.38) | AAK1MMP13MEN1GAAKMT2A | |
| SCHEMBL27908634 | 0.85 | MMP13 (0.39) | AAK1MMP13MEN1GAAKMT2A | |
| SCHEMBL7401175 | 0.85 | MMP13 (0.39) | AAK1MMP13MEN1GAAKMT2A | |
| SCHEMBL1162878 | 0.85 | MMP13 (0.39) | AAK1MMP13MEN1GAAKMT2A | |
| SCHEMBL1273585 | 0.85 | MMP13 (0.39) | AAK1MMP13MEN1GAAKMT2A | |
| SCHEMBL953166 | 0.85 | MMP13 (0.39) | AAK1MMP13MEN1GAAKMT2A | |
| SCHEMBL7401177 | 0.85 | MMP13 (0.39) | AAK1MMP13MEN1GAAKMT2A | |
| SCHEMBL2480210 | 0.85 | MMP13 (0.36) | AAK1MMP13MEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577262-B2 | Functionalized gold carbene napthaquinone complexes for use in the treatment of cancer | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-03-17 | — | — | US | disclosed |
| CN-119775170-A | Preparation method of sabatier starter intermediate | 浙江工业大学 | 2025-04-08 | — | — | CN | disclosed |
| US-20240368150-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2024-11-07 | — | — | US | disclosed |
| US-12091432-B2 | Compounds and methods for synthesizing sphingosines and glycolipids | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| EP-4405353-A1 | NEW COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | F. Hoffmann-La Roche AG (CH) | 2024-07-31 | — | — | EP | disclosed |
| CN-118324664-A | Serine derivative preparation method | 四川鸿日医药科技有限公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| CN-116903552-A | Chiral alpha-amino alcohol compound and preparation method and application thereof | 上海大学 | 2023-10-20 | — | — | CN | disclosed |
| CN-116891488-A | Condensed-cyclic compound, pharmaceutical composition containing condensed-cyclic compound and application of condensed-cyclic compound | 成都海博为药业有限公司 | 2023-10-17 | — | — | CN | disclosed |
| US-20080206805-A1 | Compounds and Related Methods for Mutant p53 Reactivation | APPELLA DANIEL H | 2008-08-28 | — | — | US | disclosed |
| US-20080206805-A1 | Compounds and Related Methods for Mutant p53 Reactivation | APPELLA DANIEL H | 2008-08-28 | — | — | US | disclosed |
| WO-2008050341-A2 | NOVEL PSYCHOTROPIC AGENTS HAVING GLUTAMATE NMDA ACTIVITY | RAMOT AT TEL-AVIV UNIVERSITY LTD (IL) | 2008-05-02 | — | — | WO | disclosed |
| US-7329775-B2 | Compounds and related methods for mutant p53 reactivation | NORTHWESTERN UNIVERSITY (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329775-B2 | Compounds and related methods for mutant p53 reactivation | NORTHWESTERN UNIVERSITY (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329775-B2 | Compounds and related methods for mutant p53 reactivation | NORTHWESTERN UNIVERSITY (US) | 2008-02-12 | — | — | US | disclosed |
| WO-2007066099-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-06-14 | — | — | WO | disclosed |
| US-20070129371-A1 | Novel ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| US-20050245616-A1 | Compounds and related methods for mutant p53 reactivation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-11-03 | — | — | US | disclosed |
| EP-1577302-A1 | NOVEL ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129371-A1 | Novel ethylenediamine derivatives | C1R, C9, C1S | AAK1 4783/4885MMP13 2771/4885MEN1 531/4885 |
| US-12577262-B2 | Functionalized gold carbene napthaquinone complexes for use in the treatment of cancer | RECQL, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS | AAK1 968/4885MMP13 4832/4885MEN1 2762/4885 |
| US-20240368150-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | BICRA, BRD4, CNR1 | AAK1 3346/4885MMP13 3805/4885MEN1 928/4885 |
| US-20050245616-A1 | Compounds and related methods for mutant p53 reactivation | TP53, TP53BP1, MDM2 | AAK1 1741/4885MMP13 3370/4885MEN1 3957/4885 |
| US-12091432-B2 | Compounds and methods for synthesizing sphingosines and glycolipids | SGMS2, SGMS1, SPHK2 | AAK1 2173/4885MMP13 2591/4885MEN1 1577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.